Novo Nordisk Faces a Legal Double Header as Earnings Approach
The Danish pharmaceutical heavyweight is fighting on two legal fronts just days before a pivotal earnings report, with…
Novo Nordisk Faces a Two-Pronged Test: Quarterly Results and a Pivotal FDA Decision
The Danish pharmaceutical giant Novo Nordisk enters a defining stretch this week, with its second-quarter earnings due on…
Novo Nordisk Faces a Double Squeeze: Lilly’s Record-Breaking Data and a High-Stakes Court Date
Eli Lilly has thrown down a fresh gauntlet in the GLP-1 arms race, unveiling late-stage data that shows…
Wegovy Pill Wins EU Approval, Yet Novo Nordisk’s Rally Faces a Jittery Wait for FDA and Earnings
The European Commission has handed Novo Nordisk a clear edge in the race to dominate the oral weight?loss…
Novo Nordisk’s Technical Rebound Faces Its Toughest Test: The Q2 Earnings Report
Novo Nordisk’s shares have clawed back 13% over the past month, pushing the stock back above its 200-day…
Novo Nordisk’s Rally Faces a Test: Medicare Tailwinds Meets Analyst Caution and a Billion-Dollar P
The past month has brought some much-needed relief to Novo Nordisk shareholders. After shedding nearly a third of…
Novo Nordisk’s Rally Faces a Pivotal Week of Data, Buybacks, and Medicare Tailwinds
The Danish drugmaker’s stock has clawed back nearly 40% from its March trough of €30.25, closing last week…
Novo Nordisk Faces a Summer of Dual Catalysts as Oral Wegovy and Medicare Converge
The Danish pharma giant is steering into a pivotal second half of 2026, with two powerful demand drivers…
Novo Nordisk Faces a High-Stakes Balancing Act: Wegovy Pill Approval vs. Escalating Cyber Threats
Novo Nordisk ended a week of stark contrasts with its shares stuck near EUR 38.90 — a modest…
Eala faces Vekic anew in Berlin, eyes rematch against Rybakina
MANILA, Philippines — With a rematch against world No. 2 Elena Rybakina at stake, Alex Eala faces Donna…
Novo Nordisk Faces a Pincer Movement: Legal Headwinds and a Crumbling GLP-1 Fortress
Novo Nordisk shares tumble 46% from peak after CVS strips Wegovy exclusivity, while legal cases over eye damage…
Novo Nordisk Faces a Two-Front Assault as CVS Drops Wegovy Exclusivity and Brazil Approves a Cheaper
CVS Caremark ends Wegovy’s exclusivity; Brazil approves Ozempic copycat. Novo faces mounting competition in US and emerging markets,…